On June 19, 2017 MetaStat, Inc. (OTCQB: MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, reported it has completed the second milestone under its pilot research project with Celgene Corporation (Press release, MetaStat, JUN 19, 2017, View Source [SID1234519622]). To date, MetaStat has received aggregate milestone payments of approximately $730,000 from Celgene pursuant to the terms of the pilot materials transfer agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to have successfully completed the second milestone and are now working on the next phase of the Celgene pilot research project," stated Douglas A. Hamilton, MetaStat’s President, CEO and Director.